Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares
IINNInspira Technologies Oxy B.H.N. Ltd. is a medical device company focused on developing advanced oxygen delivery systems and therapies for respiratory conditions. The company aims to innovate in the fields of artificial ventilation and respiratory support, utilizing proprietary technology to improve patient outcomes. Based in Israel, Inspira combines engineering expertise with clinical insights to create solutions designed for acute and chronic respiratory care applications.
Company News
Inspira Technologies Oxy (NASDAQ: IINN) announced a non-binding term sheet for acquiring an advanced liquid biopsy diagnostics business and receiving a $15 million strategic equity investment at a $180 million pre-money valuation. The acquisition includes an AI-powered platform for isolating and characterizing circulating tumor cells from blood s...
Inspira Technologies Oxy has signed a non-binding term sheet to acquire an advanced liquid biopsy diagnostics business and receive a $15 million strategic equity investment at a $180 million pre-money valuation. The acquisition includes a proprietary platform for isolating and characterizing circulating tumor cells with AI-powered analysis, targe...
Inspira Technologies reported its full-year 2024 financial results, highlighting progress in its HYLA blood sensor and INSPIRA ART core technologies, as well as the deployment of its FDA-cleared INSPIRA ART100 system to leading hospitals.
Inspira Technologies announced positive results from a clinical study of its HYLA blood sensor, achieving 96% accuracy in a key parameter compared to traditional blood test analyzers. The company plans to advance the study and submit the HYLA device for FDA approval in the second half of 2025.
Inspira Technologies has integrated a new oxygenation indicator into its AI-powered HYLA blood sensor, which is designed to enable continuous monitoring of tissue oxygenation and early detection of respiratory complications. The company is currently undergoing clinical validation of the enhanced HYLA sensor and expects to share preliminary result...
